Beta2‐agonist increases skeletal muscle interleukin 6 production and release in response to resistance exercise in men
Open Access
- 29 April 2022
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Medicine & Science in Sports
- Vol. 32 (7) , 1099-1108
Abstract
Objective Several tissues produce and release interleukin-6 (IL-6) in response to beta(2)-adrenergic stimulation with selective agonists (beta(2)-agonists). Moreover, exercise stimulates muscle IL-6 production, but whether beta(2)-agonists regulate skeletal muscle production and release of IL-6 in humans in association with exercise remains to be clarified. Thus, we investigated leg IL-6 release in response to beta(2)-agonist salbutamol in lean young men at rest and in recovery from resistance exercise. Design The study employed a randomized controlled crossover design, where 12 men ingested either salbutamol (16 mg) or placebo for 4 days, followed by the last dose (24 mg) administered 11/2 h before exercise. Arterial and femoral venous plasma IL-6 as well as femoral artery blood flow was measured before and 1/2-5 h in recovery from quadriceps muscle resistance exercise. Furthermore, vastus lateralis muscle biopsies were collected 1/2 and 5 h after exercise for determination of mRNA levels of IL-6 and Tumor Necrosis Factor (TNF)-alpha. Results Average leg IL-6 release was 1.7-fold higher (p = 0.01) for salbutamol than placebo, being 138 +/- 76 and 79 +/- 66 pg min(-1) (mean +/- SD) for salbutamol and placebo, respectively, but IL-6 release was not significantly different between treatments within specific sampling points at rest and after exercise. Muscle IL-6 mRNA was 1.5- and 1.7-fold higher (p = 0.001) for salbutamol than placebo 1/2 and 5 h after exercise, respectively, whereas no significant treatment differences were observed for TNF-alpha mRNA. Conclusions Beta(2)-adrenergic stimulation with high doses of the selective beta(2)-agonist salbutamol, preceeded by 4 consecutive daily doses, induces transcription of IL-6 in skeletal muscle in response to resistance exercise, and increases muscle IL-6 release in lean individuals.Keywords
Funding Information
- Kulturministeriet
This publication has 63 references indexed in Scilit:
- Interleukin‐6 myokine signaling in skeletal muscle: a double‐edged sword?The FEBS Journal, 2013
- Role of β-Adrenergic Receptor Regulation of TNF-α and Insulin Signaling in Retinal Müller CellsInvestigative Ophthalmology & Visual Science, 2011
- Interleukin-6 release is higher across arm than leg muscles during whole-body exerciseExperimental Physiology, 2011
- Cellular mechanisms underlying temporal changes in skeletal muscle protein synthesis and breakdown during chronic β-adrenoceptor stimulation in miceThe Journal of Physiology, 2010
- The selectivity of β‐adrenoceptor agonists at human β1‐, β2‐ and β3‐adrenoceptorsBritish Journal of Pharmacology, 2010
- Influence of Commonly Employed Resistance Exercise Protocols on Circulating IL-6 and Indices of Insulin SensitivityJournal of Strength & Conditioning Research, 2010
- Short‐term β‐adrenergic regulation of leptin, adiponectin and interleukin‐6 secretion in vivo in lean and obese subjectsDiabetes, Obesity and Metabolism, 2008
- Exercise and IL‐6 infusion inhibit endotoxin‐induced TNF‐α production in humansThe FASEB Journal, 2003
- Effects of Obesity on PharmacokineticsClinical Pharmacokinetics, 2000
- Anti-inflammatory effect of β2-agonists: Inhibition of TNF-α release from human mast cellsJournal of Allergy and Clinical Immunology, 1997